CGON
CG Oncology, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
-4/100
Last price
64.70
▼ 4.01 (5.84%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
68.68
Prev close
68.71
Day high
69.17
Day low
63.19
Volume
774.28K
Market cap
$5.64B
P/E (TTM)
—
52W range
35.80 – 80.97
Day trading desk
Gap from prior close
-0.04%
Prior close 68.71
VWAP
64.56
+0.21% from price
Relative volume
0.59×
Quiet session
Session range
9.46%
63.19 – 69.17
Position in range
25%
Near session low
ATR (14D)
3.87
5.98% of price
Prior day high
68.95
PDH
Prior day low
65.71
PDL
Bid / ask spread
—
Quote not published
Session volume
532.08K
Avg 901.27K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-9.76%
-11.7%
1M
-14.77%
-15.9%
3M
-8.83%
-13.3%
6M
-8.84%
-27.0%
YTD
+53.28%
+39.0%
1Y
+59.82%
+43.4%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CGON open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+371.08K
Net buying
Buy transactions
10
426.81K shares
Sell transactions
9
55.73K shares
Net transactions
+19
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
202.10K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 15, 26 | POST LEONARD E Director |
CONVERSION | 1.00K | $600 | Direct |
| Sep 15, 26 | POST LEONARD E Director |
SELL | 1.00K | $72.98K | Direct |
| Aug 14, 26 | POST LEONARD E Director |
CONVERSION | 1.00K | $600 | Direct |
| Aug 14, 26 | POST LEONARD E Director |
SELL | 1.00K | $74.54K | Direct |
| Jul 15, 26 | POST LEONARD E Director |
CONVERSION | 1.00K | $600 | Direct |
| Jul 15, 26 | POST LEONARD E Director |
SELL | 1.00K | $71.17K | Direct |
| Jul 10, 26 | MULAY JAMES J. Director |
CONVERSION | 24.16K | $643.51K | Direct |
| Jul 10, 26 | MULAY JAMES J. Director |
SELL | 24.16K | $1.82M | Direct |
| Jun 25, 26 | LIU BRIAN GUAN-CHYUN M.D. Director |
BUY | 371.08K | $24.81M | Indirect |
| Jun 24, 26 | POST LEONARD E Director |
CONVERSION | 5.00K | $3.00K | Direct |
| Jun 24, 26 | POST LEONARD E Director |
SELL | 5.00K | $350.00K | Direct |
| Jun 22, 26 | POST LEONARD E Director |
CONVERSION | 5.00K | $3.00K | Direct |
| Jun 22, 26 | POST LEONARD E Director |
SELL | 5.00K | $325.00K | Direct |
| Jun 15, 26 | MULAY JAMES J. Director |
CONVERSION | 1.96K | $18.93K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
KUAN ARTHUR |
Chief Executive Officer | 198.92K | Conversion of Exercise of derivative security |
LIU BRIAN GUAN-CHYUN M.D. |
Director | — | Purchase |
MULAY JAMES J. |
Director | 0 | Conversion of Exercise of derivative security |
POST LEONARD E |
Director | 0 | Conversion of Exercise of derivative security |
SONG HONG FANG |
Director | — | Sale |
Fundamentals
Market cap$5.64B
Enterprise value$4.62B
Revenue (TTM)$6.23M
Gross profit$-161.54M
EBITDA$-249.66M
Net income$-224.38M
EPS (TTM)$-2.75
Free cash flow$-113.71M
Total cash$1.03B
Total debt$8.82M
Book value / share$11.65
Shares outstanding88.64M
Float68.28M
Short % of float12.92%
Dividend yield0.00%
Beta (5Y)0.28
Valuation & profitability ratios
Trailing P/E—
Forward P/E-21.07
PEG ratio—
Price / sales—
Price / book5.46
EV / revenue742.07
EV / EBITDA-18.51
Gross margin0.00%
Operating margin-7467.68%
Profit margin0.00%
Return on equity-26.41%
Return on assets-17.67%
Debt / equity0.86
Current ratio22.22
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $4.04M | $1.14M | $204.00K | $191.00K | +254.7% |
| Operating revenue | $4.04M | $1.14M | $204.00K | $191.00K | +254.7% |
| Cost of revenue | $4.65M | $0 | $0 | — | — |
| Gross profit | -$607.00K | $1.14M | $204.00K | — | -153.3% |
| Research & development | $116.64M | $82.10M | $45.75M | $29.03M | +42.1% |
| Selling, general & admin | $73.53M | $33.70M | $9.90M | $6.41M | +118.2% |
| Total operating expense | $190.17M | $115.81M | $55.65M | $35.44M | +64.2% |
| Operating income | -$190.77M | -$114.67M | -$55.45M | -$35.25M | -66.4% |
| Net interest income | $29.93M | $26.62M | $6.90M | -$1.00K | +12.4% |
| Pre-tax income | -$161.00M | -$88.04M | -$48.61M | -$35.44M | -82.9% |
| Net income | -$161.00M | -$88.04M | -$48.61M | -$35.44M | -82.9% |
| Net income to common | -$161.00M | -$88.04M | -$67.80M | -$43.79M | -82.9% |
| Basic EPS | -2.08 | -1.41 | -15.65 | -11.71 | -47.5% |
| Diluted EPS | -2.08 | -1.41 | -15.65 | -11.71 | -47.5% |
| EBIT | -$190.77M | -$114.67M | -$55.45M | -$35.25M | -66.4% |
| EBITDA | -$189.33M | -$114.63M | -$55.43M | -$35.23M | -65.2% |
| Basic shares | 77.30M | 62.50M | 4.33M | 3.74M | +23.7% |
| Diluted shares | 77.30M | 62.50M | 4.33M | 3.74M | +23.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $32.49M | $257.07M | $8.27M | $88.14M | — | -87.4% |
| Cash & short-term investments | $742.15M | $742.00M | $187.67M | $143.48M | — | +0.0% |
| Accounts receivable | $688.00K | $0 | — | — | — | — |
| Inventory | $1.56M | $0 | — | — | — | — |
| Total current assets | $759.48M | $754.21M | $194.12M | $147.21M | — | +0.7% |
| Property, plant & equipment | $19.57M | $493.00K | $491.00K | $506.00K | — | +3,869.0% |
| Goodwill & intangibles | $10.87M | $0 | — | — | — | — |
| Total assets | $791.59M | $754.80M | $199.30M | $147.75M | — | +4.9% |
| Total current liabilities | $30.84M | $21.37M | $14.25M | $15.43M | — | +44.3% |
| Current debt | — | — | — | $8.97M | $2.94M | — |
| Long-term debt | $3.00M | — | — | $6.53M | $12.06M | — |
| Total debt | $7.02M | $238.00K | $461.00K | $15.94M | — | +2,850.0% |
| Total liabilities | $38.99M | $21.42M | $14.51M | $22.57M | — | +82.0% |
| Retained earnings | -$378.98M | -$217.98M | -$129.94M | -$81.33M | — | -73.9% |
| Shareholder equity | $752.60M | $733.38M | $184.79M | $125.18M | — | +2.6% |
| Working capital | $728.64M | $732.84M | $179.87M | $131.78M | — | -0.6% |
| Net tangible assets | $741.73M | $733.38M | $184.79M | $125.18M | — | +1.1% |
| Shares issued | 80.69M | 76.15M | 63.48M | 63.48M | — | +6.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$161.00M | -$88.04M | -$48.61M | -$35.44M | — | -82.9% |
| Depreciation & amortisation | $1.45M | $32.00K | $17.00K | $15.00K | — | +4,415.6% |
| Stock-based compensation | $26.68M | $11.40M | $1.53M | $676.00K | — | +134.0% |
| Change in working capital | $2.28M | $2.91M | $3.44M | $4.44M | — | -21.7% |
| Operating cash flow | -$132.35M | -$78.71M | -$45.68M | -$29.80M | — | -68.1% |
| Capital expenditure | -$134.00K | -$234.00K | — | -$14.00K | -$97.00K | +42.7% |
| Investing cash flow | -$245.82M | -$300.76M | -$121.19M | -$55.35M | — | +18.3% |
| Financing cash flow | $153.59M | $628.28M | $87.00M | $119.69M | — | -75.6% |
| Free cash flow | -$132.48M | -$78.95M | -$45.68M | -$29.82M | — | -67.8% |
| End cash position | $32.49M | $257.07M | $8.27M | $88.14M | — | -87.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $1.16M | $1.08M | $2.32M | $1.67M | $0 | — | +6.8% |
| Operating revenue | $1.16M | $1.08M | $2.32M | $1.67M | $0 | — | +6.8% |
| Cost of revenue | $3.92M | $2.96M | $3.07M | $1.58M | $0 | — | +32.5% |
| Gross profit | -$2.77M | -$1.88M | -$748.00K | $89.00K | $0 | — | -47.3% |
| Research & development | $54.66M | $43.73M | $29.96M | $27.88M | $31.33M | — | +25.0% |
| Selling, general & admin | $28.98M | $20.78M | $17.99M | $23.33M | $17.41M | — | +39.4% |
| Total operating expense | $83.63M | $64.51M | $47.95M | $51.22M | $48.74M | — | +29.6% |
| Operating income | -$86.40M | -$66.39M | -$48.70M | -$51.13M | -$48.74M | — | -30.1% |
| Net interest income | $7.33M | $6.29M | $7.44M | $7.42M | $7.32M | — | +16.6% |
| Pre-tax income | -$79.06M | -$60.20M | -$41.31M | -$43.81M | -$41.43M | — | -31.3% |
| Net income | -$79.06M | -$60.20M | -$41.31M | -$43.81M | -$41.43M | — | -31.3% |
| Net income to common | -$79.06M | -$60.20M | -$41.31M | -$43.81M | -$41.43M | — | -31.3% |
| Basic EPS | -0.90 | -0.71 | — | -0.57 | -0.54 | -0.45 | -26.8% |
| Diluted EPS | -0.90 | -0.71 | — | -0.57 | -0.54 | -0.45 | -26.8% |
| EBIT | -$86.40M | -$66.39M | -$48.70M | -$51.13M | -$48.74M | — | -30.1% |
| EBITDA | -$85.55M | -$65.55M | -$47.85M | -$50.71M | -$48.59M | — | -30.5% |
| Basic shares | 88.20M | 84.52M | — | 76.73M | 76.23M | 76.19M | +4.4% |
| Diluted shares | 88.20M | 84.52M | — | 76.73M | 76.23M | 76.19M | +4.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $19.64M | $33.70M | $32.49M | $45.15M | $14.62M | -41.7% |
| Cash & short-term investments | $1.03B | $1.08B | $742.15M | $680.26M | $661.05M | -4.5% |
| Accounts receivable | $417.00K | $1.27M | $688.00K | $515.00K | — | -67.3% |
| Inventory | $1.00M | $1.49M | $1.56M | $1.50M | — | -32.8% |
| Total current assets | $1.05B | $1.10B | $759.48M | $695.79M | $673.03M | -4.8% |
| Property, plant & equipment | $20.44M | $19.59M | $19.57M | $19.53M | $1.22M | +4.3% |
| Goodwill & intangibles | $10.84M | $10.86M | $10.87M | $14.48M | — | -0.1% |
| Total assets | $1.09B | $1.14B | $791.59M | $729.91M | $701.45M | -4.4% |
| Total current liabilities | $47.24M | $35.22M | $30.84M | $30.53M | $30.38M | +34.1% |
| Long-term debt | $3.00M | $3.00M | $3.00M | $3.00M | — | 0.0% |
| Total debt | $8.82M | $7.58M | $7.02M | $7.24M | $994.00K | +16.4% |
| Total liabilities | $56.54M | $43.48M | $38.99M | $42.27M | $31.09M | +30.0% |
| Retained earnings | -$518.23M | -$439.18M | -$378.98M | -$337.67M | -$293.86M | -18.0% |
| Shareholder equity | $1.03B | $1.09B | $752.60M | $687.64M | $670.36M | -5.7% |
| Working capital | $1.00B | $1.07B | $728.64M | $665.26M | $642.65M | -6.0% |
| Net tangible assets | $1.02B | $1.08B | $741.73M | $673.17M | $670.36M | -5.8% |
| Shares issued | 88.31M | 88.01M | 80.69M | 78.28M | 76.23M | +0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$79.06M | -$60.20M | -$41.31M | -$43.81M | -$41.43M | -31.3% |
| Depreciation & amortisation | $850.00K | $841.00K | $849.00K | $416.00K | $156.00K | +1.1% |
| Stock-based compensation | $14.33M | $6.47M | $7.19M | $7.33M | $7.01M | +121.4% |
| Change in working capital | $14.38M | -$5.78M | -$3.98M | -$2.87M | $8.66M | +348.9% |
| Operating cash flow | -$46.41M | -$56.94M | -$36.22M | -$38.89M | -$27.96M | +18.5% |
| Capital expenditure | -$468.00K | -$304.00K | -$7.00K | -$97.00K | -$14.00K | -53.9% |
| Investing cash flow | $30.43M | -$334.85M | -$75.50M | $15.04M | $1.41M | +109.1% |
| Financing cash flow | $1.92M | $393.00M | $99.07M | $54.37M | -$296.00K | -99.5% |
| Free cash flow | -$46.88M | -$57.25M | -$36.22M | -$38.99M | -$27.97M | +18.1% |
| End cash position | $19.64M | $33.70M | $32.49M | $45.15M | $14.62M | -41.7% |
Options analytics
Put / call volume
0.44
Call-heavy session
Put / call open interest
0.39
Positioning, not flow
Max pain
70.00
+10.0% from spot
ATM implied vol
123.9%
Nearest strike to spot
Skew (10% OTM)
+27.4%
Puts bid over calls
Call volume
407
Contracts, this expiry
Put volume
180
Contracts, this expiry
Heaviest call OI
75.00
3.87K contracts
Heaviest put OI
50.00
1.46K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.64 | -0.90 | -40.1% |
| Mar 2026 | -0.54 | -0.71 | -31.5% |
| Dec 2025 | -0.58 | -0.51 | +12.6% |
| Sep 2025 | -0.55 | -0.57 | -4.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.81 | 12 | $534.48K | -67.9% |
| Next quarter | -0.84 | 12 | $531.18K | -77.1% |
| Current year | -3.23 | 12 | $4.47M | +10.6% |
| Next year | -3.02 | 12 | $83.52M | +1,768.5% |
Analyst targets & ownership
Mean target$91.08
High target$108.00
Low target$79.00
Implied upside40.77%
Analyst count13
ConsensusNONE
Strong buy / Buy4 / 10
Hold1
Sell / Strong sell0 / 0
Held by insiders0.23%
Held by institutions113.64%
Institutions holding343
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
68.84
-6.01% from price
SMA 20
71.57
-11.08% from price
SMA 50
73.78
-13.74% from price
SMA 100
69.67
-7.13% from price
SMA 200
64.19
-0.86% from price
EMA 12
69.42
-6.80% from price
EMA 26
71.47
-9.47% from price
EMA 50
72.01
-10.15% from price
RSI (14)
34.1
Neutral
MACD (12,26,9)
-2.05
Hist -0.78
ATR (14)
3.87
6.08% of price
Realised vol 30D
45.9%
Annualised
Bollinger upper
78.73
20, 2σ
Bollinger lower
64.40
20, 2σ
50 / 200 cross
Golden
73.78 vs 64.19
Trend bias
Below 200
-0.86%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.11
More volatile than market
Correlation to SPY
0.25
Largely independent
Realised vol 30D
45.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-27.4%
Peak to trough
Max drawdown 5Y
-67.5%
Peak to trough
ATR 14
3.87
6.08% of price
Beta (reported)
0.28
5Y monthly, from filing
Short interest
Shares short
11.25M
Prior 11.25M
Change vs prior
+0.1%
Shorts adding
% of float
12.92%
Elevated
% of shares out
12.70%
Against total outstanding
Days to cover
16.1
Crowded exit
Float
68.28M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 7, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Aug 7, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| May 19, 26 | Wolfe Research | INITIATED | — | Peer Perform |
| May 18, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 14, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| May 11, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| May 11, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| May 11, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| May 11, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Apr 27, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Apr 17, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-06-08
Corporate Changes & Voting Matters
8-K · 2026-05-26
Periodic Financial Reports
10-Q · 2026-05-08
Annual Report to Shareholders
ARS · 2026-04-24
Corporate Changes & Voting Matters
8-K · 2026-04-13
Offering Registrations
S-8 · 2026-02-27
Corporate Changes & Voting Matters
8-K · 2026-01-13
Headlines
3 Stocks Call Traders Are Targeting Today
Schaeffer's Investment Research · 25d ago
CG Oncology (CGON) Stock Looks Fully Priced After A 160% Run
Simply Wall St. · 34d ago
Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsight
PR Newswire · 42d ago
BofA Adjusts Price Target on CG Oncology to $88 From $87
MT Newswires · 61d ago
RBC Adjusts PT on CG Oncology to $79 From $81, Maintains Outperform Speculative Risk Rating
MT Newswires · 61d ago
CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates
Zacks · 62d ago
CG Oncology Q2 Net Loss Widens
MT Newswires · 62d ago
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
GlobeNewswire · 62d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.